ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 220 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2021. The put-call ratio across all filers is 1.38 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,436,214 | +5.0% | 68,337 | +35.9% | 0.01% | +12.5% |
| Q2 2023 | $2,319,970 | +15.0% | 50,292 | 0.0% | 0.01% | +14.3% |
| Q1 2023 | $2,016,709 | -35.4% | 50,292 | -25.3% | 0.01% | -41.7% |
| Q4 2022 | $3,119,909 | +59.3% | 67,341 | +42.4% | 0.01% | +50.0% |
| Q3 2022 | $1,958,000 | -30.6% | 47,289 | 0.0% | 0.01% | -27.3% |
| Q2 2022 | $2,821,000 | -12.4% | 47,289 | +6.7% | 0.01% | +10.0% |
| Q1 2022 | $3,220,000 | -9.4% | 44,338 | +4.9% | 0.01% | 0.0% |
| Q4 2021 | $3,556,000 | -6.4% | 42,284 | +0.4% | 0.01% | -16.7% |
| Q3 2021 | $3,800,000 | +0.7% | 42,132 | +6.5% | 0.01% | 0.0% |
| Q2 2021 | $3,773,000 | -13.6% | 39,570 | +3.2% | 0.01% | -20.0% |
| Q1 2021 | $4,368,000 | -17.1% | 38,360 | +0.8% | 0.02% | -21.1% |
| Q4 2020 | $5,268,000 | +57.9% | 38,055 | -6.3% | 0.02% | +46.2% |
| Q3 2020 | $3,337,000 | +3.8% | 40,604 | -1.2% | 0.01% | 0.0% |
| Q2 2020 | $3,215,000 | +22.8% | 41,096 | -30.3% | 0.01% | 0.0% |
| Q1 2020 | $2,619,000 | +4.1% | 58,944 | 0.0% | 0.01% | +44.4% |
| Q4 2019 | $2,517,000 | +28.5% | 58,944 | +28.7% | 0.01% | +12.5% |
| Q3 2019 | $1,959,000 | +228.1% | 45,800 | +387.2% | 0.01% | +300.0% |
| Q2 2019 | $597,000 | -8.4% | 9,400 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $652,000 | +59.4% | 9,400 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $409,000 | -43.0% | 9,400 | 0.0% | 0.00% | -33.3% |
| Q3 2018 | $718,000 | -0.7% | 9,400 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $723,000 | +50.9% | 9,400 | 0.0% | 0.00% | +50.0% |
| Q1 2018 | $479,000 | +9.9% | 9,400 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $436,000 | -13.0% | 9,400 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $501,000 | -14.2% | 9,400 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $584,000 | -8.3% | 9,400 | 0.0% | 0.00% | -33.3% |
| Q1 2017 | $637,000 | -3.6% | 9,400 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $661,000 | -0.9% | 9,400 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $667,000 | +45.0% | 9,400 | 0.0% | 0.00% | +50.0% |
| Q2 2016 | $460,000 | -22.7% | 9,400 | 0.0% | 0.00% | -33.3% |
| Q1 2016 | $595,000 | -71.8% | 9,400 | -50.0% | 0.00% | -25.0% |
| Q4 2015 | $2,108,000 | +132.9% | 18,800 | +100.0% | 0.00% | 0.0% |
| Q3 2015 | $905,000 | -5.9% | 9,400 | 0.0% | 0.00% | 0.0% |
| Q2 2015 | $962,000 | +64.7% | 9,400 | 0.0% | 0.00% | +100.0% |
| Q1 2015 | $584,000 | +41.7% | 9,400 | 0.0% | 0.00% | 0.0% |
| Q4 2014 | $412,000 | -22.6% | 9,400 | 0.0% | 0.00% | 0.0% |
| Q3 2014 | $532,000 | +26.1% | 9,400 | 0.0% | 0.00% | 0.0% |
| Q2 2014 | $422,000 | – | 9,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |